Loading ...
Sorry, an error occurred while loading the content.

SciClone Strengthens Latin American Position for Zadixin in Hepatitis C

Expand Messages
  • claudine intexas
    SciClone Strengthens Latin American Position for Zadaxin in Hepatitis C SAN MATEO, Calif., Sept. 28 /PRNewswire/ -- SciClone Pharmaceuticals (Nasdaq: SCLN)
    Message 1 of 1 , Sep 29, 2000
    • 0 Attachment
      SciClone Strengthens Latin American Position for
      Zadaxin in Hepatitis C

      SAN MATEO, Calif., Sept. 28 /PRNewswire/ --
      SciClone Pharmaceuticals (Nasdaq: SCLN) announced
      today that it has
      received
      an issued patent in Mexico for the use of the
      Company's lead drug,
      ZADAXIN,
      for the treatment of hepatitis C. SciClone also
      announced that Peru
      has
      expanded ZADAXIN's approval to include the treatment
      of hepatitis C as
      well
      as
      the previously approved hepatitis B.
      In Latin America, ZADAXIN is approved for sale in
      Mexico, Peru,
      Argentina
      and Venezuela. Approved indications include hepatitis
      B, hepatitis C
      and
      as a
      viral vaccine adjuvant for patients with weakened
      immune systems.
      "The Mexican hepatitis C patent is of particular
      significance as
      Mexico
      is
      our first North American market and clearly one of the
      most important
      Latin
      American market," said Donald R. Sellers, SciClone's
      President and
      Chief Executive Officer. "Our ZADAXIN launch in
      Mexico is in full
      swing."
      Sellers noted that SciClone will be a major
      participant at the
      16th Latin American Congress of Hepatology held this
      year in Mexico
      throughout
      the first week of October. The upcoming congress will
      be the Company's
      most
      significant medical education opportunity to date with
      Latin American
      physicians, researchers and hepatitis opinion leaders.
      SciClone also announced that ZADAXIN approval has
      been expanded
      from
      hepatitis B to include hepatitis C in Sri Lanka.
      ZADAXIN is approved for sale in 20 countries,
      principally for the
      treatment of hepatitis B and hepatitis C and as a
      vaccine adjuvant for
      patients with weakened immune systems. SciClone plans
      to start a
      phase 3 ZADAXIN hepatitis C program in the U.S. by the
      end of the year.
      The
      U.S. program will be complemented by a phase 3
      hepatitis C program in
      Europe
      to be conducted by Sigma-Tau S.p.A., SciClone's
      partner. ZADAXIN is in
      phase
      2 development in the U.S. in combination with
      lamivudine for the
      treatment
      of
      hepatitis B. SciClone plans to initiate U.S. phase 2
      ZADAXIN clinical
      programs in liver cancer and malignant melanoma by the
      end of the year.
      A
      phase 3 ZADAXIN hepatitis B study is ongoing in Japan.
      ZADAXIN has
      been
      administered to over 3,000 subjects in over 70
      clinical trials covering
      a
      broad range of diseases, and an estimated 7,000
      patients commercially,
      with
      virtually no serious drug related side effects or
      toxicities.
      SciClone Pharmaceuticals is a global specialty
      pharmaceutical
      company
      that
      develops and commercializes novel medicines for the
      treatment of a
      broad
      range
      of the world's most serious diseases. The Company is
      currently
      targeting
      malignant melanoma, liver cancer, hepatitis B,
      hepatitis C, HIV,
      drug-resistant tuberculosis and cystic fibrosis.
      Press releases and
      corporate
      information from SciClone Pharmaceuticals are
      available on the Internet
      at
      www.sciclone.com or by calling the Company's Investor
      Relations
      Department
      at
      800-724-2566. SciClone's Common Stock is listed on
      The Nasdaq National
      Market(R) under the symbol SCLN.
      The information in this press release includes
      certain
      forward-looking
      statements concerning the Company's current
      expectations regarding
      future
      events, including continuing ZADAXIN revenue growth,
      the commercial
      success
      of
      ZADAXIN in Latin America, particularly in Mexico, and
      the ongoing and
      prospective development and commercialization of
      ZADAXIN immunotherapy
      in
      the
      U.S., Europe and Japan for cancer, hepatitis B and
      hepatitis C, the
      timing
      of
      the start and potential for success of the Company's
      U.S. phase 2
      programs
      for
      cancer and its ZADAXIN phase 3 program for hepatitis C
      in the U.S., and
      Sigma-Tau's ZADAXIN phase 3 program for hepatitis C in
      Europe. Due to
      market
      factors and the nature of product development and the
      regulatory
      approval
      process, the forward-looking statements contained in
      this press release
      are
      subject to risks and uncertainties, including those
      reflected in the
      Company's
      filings with the Securities and Exchange Commission,
      particularly the
      Company's Annual Report on Form 10-K for the year
      ended December 31,
      1999.

      SOURCE SciClone Pharmaceuticals
      -0- 09/28/2000
      /CONTACT: investors, Ruth Koh of SciClone
      Pharmaceuticals,
      650-358-3437; or media, Ana Kapor of Noonan Russo
      Communications, Inc.,
      415-677-4455, for SciClone Pharmaceuticals/
      /Company News On-Call:
      http://www.prnewswire.com/comp/775865.html
      or
      fax,
      800-758-5804, ext. 775865/
      /Web site: http://www.sciclone.com/
      (SCLN)


      __________________________________________________
      Do You Yahoo!?
      Yahoo! Photos - 35mm Quality Prints, Now Get 15 Free!
      http://photos.yahoo.com/
    Your message has been successfully submitted and would be delivered to recipients shortly.